Below are the most recent publications written about "Amyloid" by people in Profiles.
-
Ding H, Lyu C, Karjadi C, Sunderaraman P, Young CB, Mormino EC, Low S, Devine S, Gifford K, Au R, Lin H. Association of the digital clock drawing test with amyloid and tau PET biomarkers in low age risk adults. Sci Rep. 2025 Apr 01; 15(1):11104.
-
Lam AD, Thibault EG, Mayblyum DV, Hsieh S, Pellerin KR, Sternberg EJ, Viswanathan A, Buss S, Sarkis RA, Jacobs HIL, Johnson KA, Sperling RA. Association of Seizure Foci and Location of Tau and Amyloid Deposition and Brain Atrophy in Patients With Alzheimer Disease and Seizures. Neurology. 2024 Nov 12; 103(9):e209920.
-
Wang J, Lin Q, Qiu C, McClements DJ, Ji H, Jin Z. Composite biopolymer foams fabricated from natural aldehyde functionalized chitosan-whey protein amyloid fibrils: Application for removal of phthalate esters from water. Carbohydr Polym. 2025 Jan 15; 348(Pt A):122789.
-
Ferguson CM, Hildebrand S, Godinho BMDC, Buchwald J, Echeverria D, Coles A, Grigorenko A, Vangjeli L, Sousa J, McHugh N, Hassler M, Santarelli F, Heneka MT, Rogaev E, Khvorova A. Silencing Apoe with divalent-siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease. Alzheimers Dement. 2024 04; 20(4):2632-2652.
-
Brand AL, Lawler PE, Bollinger JG, Li Y, Schindler SE, Li M, Lopez S, Ovod V, Nakamura A, Shaw LM, Zetterberg H, Hansson O, Bateman RJ. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review. Alzheimers Res Ther. 2022 12 27; 14(1):195.
-
Prokaeva T, Klimtchuk ES, Feschenko P, Spencer B, Cui H, Burks EJ, Aslebagh R, Muneeruddin K, Shaffer SA, Varghese E, Berk JL, Connors LH. An additive destabilising effect of compound T60I and V122I substitutions in ATTRv amyloidosis. Amyloid. 2023 Jun; 30(2):141-152.
-
Nicastro LK, de Anda J, Jain N, Grando KCM, Miller AL, Bessho S, Gallucci S, Wong GCL, T?kel ?. Assembly of ordered DNA-curli fibril complexes during Salmonella biofilm formation correlates with strengths of the type I interferon and autoimmune responses. PLoS Pathog. 2022 08; 18(8):e1010742.
-
Farzadfard A, Pedersen JN, Meisl G, Somavarapu AK, Alam P, Goks?yr L, Nielsen MA, Sander AF, Knowles TPJ, Pedersen JS, Otzen DE. The C-terminal tail of a-synuclein protects against aggregate replication but is critical for oligomerization. Commun Biol. 2022 02 10; 5(1):123.
-
Janssen O, Jansen WJ, Vos SJB, Boada M, Parnetti L, Gabryelewicz T, Fladby T, Molinuevo JL, Villeneuve S, Hort J, Epelbaum S, Lle? A, Engelborghs S, van der Flier WM, Landau S, Popp J, Wallin A, Scheltens P, Rikkert MO, Snyder PJ, Rowe C, Ch?telat G, Ru?z A, Marqui? M, Chipi E, Wolfsgruber S, Heneka M, Boecker H, Peters O, Jarholm J, Rami L, Tort-Merino A, Binette AP, Poirier J, Rosa-Neto P, Cerman J, Dubois B, Teichmann M, Alcolea D, Fortea J, S?nchez-Saudin?s MB, Ebenau J, Pocnet C, Eckerstr?m M, Thompson L, Villemagne V, Buckley R, Burnham S, Delarue M, Freund-Levi Y, Wallin ?K, Ramakers I, Tsolaki M, Soininen H, Hampel H, Spiru L, Tijms B, Ossenkoppele R, Verhey FRJ, Jessen F, Visser PJ. Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimers Dement. 2022 10; 18(10):1832-1845.
-
Weiner MW, Aisen PS, Beckett LA, Green RC, Jagust W, Morris JC, Okonkwo O, Perrin RJ, Petersen RC, Rivera Mindt M, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ. Editorial: How Will Aducanumab Approval Impact AD Research? J Prev Alzheimers Dis. 2021; 8(4):391-392.